Provention Bio, Inc. (2VB.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
As of 09:15AM CET. Market open.
| Previous Close | 8.33 |
| Open | 8.57 |
| Bid | 8.57 x 0 |
| Ask | 8.91 x 0 |
| Day's Range | 8.57 - 8.57 |
| 52 Week Range | 3.22 - 10.00 |
| Volume | |
| Avg. Volume | 167 |
| Market Cap | 763.427M |
| Beta (5Y Monthly) | 2.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.56 |
| Earnings Date | Feb 22, 2023 - Feb 27, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.79 |
- Simply Wall St.
Market Sentiment Around Loss-Making Provention Bio, Inc. (NASDAQ:PRVB)
Provention Bio, Inc. ( NASDAQ:PRVB ) is possibly approaching a major achievement in its business, so we would like to...
- Simply Wall St.
While institutions invested in Provention Bio, Inc. (NASDAQ:PRVB) benefited from last week's 7.6% gain, individual investors stood to gain the most
A look at the shareholders of Provention Bio, Inc. ( NASDAQ:PRVB ) can tell us which group is most powerful. The group...
- Motley Fool
Why Shares of Provention Bio Went Up 30.3% in November
Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.
© 2023 Yahoo. All rights reserved.
